Sarepta Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
SRPT$17.24-3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,103,010 | $428,430 |
| Short-term investments | 251,782 | 1,247,820 |
| Accounts receivable, net | 601,988 | 400,327 |
| Inventory | 749,960 | 322,859 |
| Manufacturing-related deposits and prepaids | 276,262 | 102,181 |
| Other current assets | 90,461 | 77,714 |
| Total current assets | 3,073,463 | 2,579,331 |
| Property and equipment, net | 340,336 | 227,154 |
| Right of use assets | 148,310 | 129,952 |
| Non-current inventory | 187,986 | 191,368 |
| Non-current investments | 133,163 | — |
| Other non-current assets | 79,915 | 136,771 |
| Total assets | $3,963,173 | $3,264,576 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $214,442 | $164,918 |
| Accrued expenses | 373,513 | 314,997 |
| Deferred revenue, current portion | 130,256 | 50,416 |
| Current portion of long-term debt | — | 105,483 |
| Other current liabilities | 13,473 | 17,845 |
| Total current liabilities | 731,684 | 653,659 |
| Long-term debt | 1,137,124 | 1,132,515 |
| Lease liabilities, net of current portion | 192,473 | 140,965 |
| Deferred revenue, net of current portion | 325,000 | 437,000 |
| Contingent consideration | 47,400 | 38,100 |
| Other non-current liabilities | 1,750 | 3,000 |
| Total liabilities | 2,435,431 | 2,405,239 |
| Commitments and contingencies (Note 22) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding | — | — |
| Common stock, $0.0001 par value, 198,000,000 shares authorized; 96,900,496 and 93,731,831 issued and outstanding at December 31, 2024 and 2023, respectively | 10 | 9 |
| Additional paid-in capital | 5,738,924 | 5,304,623 |
| Accumulated other comprehensive (loss) income, net of tax | (218) | 918 |
| Accumulated deficit | (4,210,974) | (4,446,213) |
| Total stockholders’ equity | 1,527,742 | 859,337 |
| Total liabilities and stockholders’ equity | $3,963,173 | $3,264,576 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.